ENGAGE AF-TIMI 48 was a randomised , double-blind trial in which patients with atrial fibrillation were assigned to warfarin to achieve a target international normalised ratio of 20-30 , or to higher-dose ( 60 mg ) or lower-dose ( 30 mg ) edoxaban once daily .